Mimedx Group, Inc. MDXG
Medical/Dental Instruments · data as of November 13, 2026
Mimedx Group, Inc. (MDXG) is a healthcare company listed in the US with a market value of about $468M. In the twelve months to September 30, 2026 it had revenue of $304M and net income of -$19M, a net margin of -6.3%.
Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is financial health (5/5); the weakest is value (0/5).
Key numbers: a price to free cash flow of 26.2, 5-year revenue growth of 11% a year, a 5-year average ROIC of 2%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 93% below the current price.
About Mimedx Group
Mimedx Group is listed in the US and classified in medical/dental instruments. Revenue went from $118M in 2014 to $419M in 2025, growth of about 12.2% a year. It was profitable in 5 of the last 10 years in our data. Its share count rose by 33% over three years (dilution for shareholders). It spends 4% of revenue on research and development.
Score: 1.8 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 5-year revenue growth above 8% a year
- ROE above 15%
- More cash than debt, or low debt to equity
- Positive free cash flow
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $304M | $419M | $349M | $321M | $268M | $242M | $248M | $299M | $359M | $321M | $245M |
| Net income | -$19M | $49M | $42M | $58M | -$30M | -$10M | -$49M | -$26M | -$30M | $65M | $390000 |
| Free cash flow | $18M | — | — | $25M | -$19M | -$5M | — | — | — | — | — |
| EPS (diluted) | $-0.13 | $0.32 | $0.28 | $0.37 | $-0.33 | $-0.15 | $-0.77 | $-0.24 | $-0.28 | $0.56 | $0.00 |
| Net margin | -6.3% | 11.6% | 12.2% | 18.1% | -11.3% | -4.2% | -19.9% | -8.6% | -8.3% | 20.2% | 0.2% |
| ROIC | — | 16.8% | 19.8% | 15.0% | -32.5% | -10.1% | -67.3% | -19.0% | -6.2% | 49.5% | 1.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $7.00, 118% above the current price; targets range from $6.00 to $8.00; the consensus rating is “none”; expected EPS is $-0.09 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Mimedx Group stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 93% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Mimedx Group pay a dividend?
Not currently.
Is Mimedx Group a good stock to buy?
We do not give buy or sell advice. Mimedx Group scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.